Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a single-institution, single arm, open label, window of opportunity clinical trial that will act as a Master Protocol with a primary objective to assess pharmacodynamic effects of the novel study drugs in subjects with resectable solid tumor malignancies.
Each Sub-protocol conducted under the Master Protocol will evaluate different novel therapeutic agent(s).
Estimated enrollment is 15 subjects per Sub-Protocol.
Full description
Patients will have a short-course (4-weeks) administration of a given compound in the timeframe between the diagnostic biopsy and the surgical resection. A pre-treatment tumor biopsy will be obtained, and blood samples will be collected before, during, and at the end of treatment.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Other protocol defined inclusion/exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
2 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal